Yesterday afternoon, Dr. Jan Lundberg, Lilly's executive vice-president of science and sechnology, participated on a Lilly-sponsored panel at the 2012 BIO international Convention. The panelists discussed the growing trend of pre-competitive collaboration, a new research model which is intended to encourage collaboration and productivity, ultimately leading to an increased number of new, innovative medicines and therapies for patients. The research model exists in multiple forms, including public-private partnerships.
Pre-competitive collaboration is a great driver of innovation. As Dr. Lundberg said, the biopharmaceutical industry faces a wide variety of potential problems: pipeline issues, patent cliffs, shrinking R&D budgets , uncertainty in the regulatory space, declining investment by venture capitalists, difficulties in clinical trials, and tough scientific issues. Lilly currently participates in over 40 of these collaborative partnerships around the world. One such example is the NCATS partnership Lilly and other biopharmaceutical companies are participating in with the National Institute for Health.
Science and disease are global, and partnerships should be too. We need to optimize collaboration--in reality, there has to be collaboration all across the value chain from all players. Increased R&D collaboration and productivity can mean an increased number of innovative medicines. The ultimate success of these partnerships will be measured by the speed of delivery of new medicines to patients in need. The continued support of programs that encourage the exchange of ideas, expertise and tools between these research communities will hopefully improve and accelerate patients' access to novel treatments.